Oxidant/antioxidant status in blood of patients with malignant breast tumour and benign breast disease

Citations Over TimeTop 10% of 2002 papers

Abstract

The aim of this study was to investigate the alterations in lipid peroxidation and antioxidant enzyme defences in the blood of patients with malignant breast tumour and benign breast disease. Forty patients with malignant breast tumour, 20 patients with benign breast disease and also 20 healthy control subjects were recruited for the study. Malondialdehyde levels in plasma and erythrocytes, and the activities of erythrocyte CuZn-superoxide dismutase, catalase, glutathione peroxidase and glucose-6-phosphate dehydrogenase were measured. Malondialdehyde levels were higher in patients with both benign breast disease and malignant breast tumour compared with control subjects. The activities of all antioxidant enzymes were higher in patients with malignant breast tumour, while only glutathione peroxidase and CuZn-superoxide dismutase activities were higher in patients with benign breast disease. Except for glucose-6-phosphate dehydrogenase, the antioxidant enzymes studied correlated positively with the malondialdehyde levels in patients with malignant breast tumour. On the other hand, only glucose-6-phosphate dehydrogenase activity was increased by the level of malignancy. The activity increases in erythrocyte antioxidant enzymes may be a compensatory upregulation in response to increased oxidative stress especially in patients with malignant breast tumour.

Related Papers

• → Importance of the lipid peroxidation biomarkers and methodological aspects FOR malondialdehyde quantification(2009)418 cited
• → Optimized steps in determination of malondialdehyde (MDA) standards on diagnostic of lipid peroxidation(2018)18 cited
• → An inter-laboratory validation of methods of lipid peroxidation measurement in UVA-treated human plasma samples(2010)66 cited
• [Malondialdehyde (MDA) as a lipid peroxidation marker].(2004)
• Paraquat and lipid peroxidation.(1982)